共 70 条
[1]
Bray F(2018)Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 68 394-424
[2]
Ferlay J(2008)Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials J Clin Oncol 26 4906-4911
[3]
Soerjomataram I(2016)Comparison of panitumumab plus irinotecan and cetuximab plus irinotecan for KRAS wild-type metastatic colorectal cancer Anticancer Res 36 3531-3536
[4]
Mitry E(2014)FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 1065-1075
[5]
Fields AL(2008)Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer Pharmacotherapy 28 742-754
[6]
Bleiberg H(2004)Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335-2342
[7]
Yamaguchi T(2005)Bevacizumab–current status and future directions Ann Oncol 16 999-1004
[8]
Iwasa S(2020)Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 (AIO KRK0306) Ann Oncol 31 72-78
[9]
Nagashima K(2021)Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study ESMO Open 6 585-606
[10]
Heinemann V(2018)Comparative effectiveness and safety of monoclonal antibodies (bevacizumab, cetuximab, and panitumumab) in combination with chemotherapy for metastatic colorectal cancer: a systematic review and meta-analysis BioDrugs 32 280-605